← SynDRA
GEFITINIB
SynDRA canonical compound SYN0002694 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- EGFR
- ABCB1
- PRKD1
- PIM3
- PHKG2
- PHKG1
- NUAK2
- NLK
- MYLK2
- MKNK2
- MKNK1
- MINK1
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ZD1839
- iressa
- ZD 1839
- NSC-759856
- ZD-1839
- Gefitinib mylan
- Iressa
- Gefitini
- IRE
- Irressat
- Gefitinib [USAN]
- Iressa (TN)
- Iressa(TM)
- CU-00000000396-1
- Gefitinib,Iressa, ZD1839
- Gefitinib (JAN/USAN/INN)
- ZD-1839, Iressa, Gefitinib
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
- N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
- 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
- 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
- gefitinib (zd1839)
- Gefitinib (GMP)
- MFCD04307832
- CHEMBL939
- NSC 759856
- S65743JHBS
- CHEBI:49668
- 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
- NCGC00159455-02
- N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
- 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-
- CCRIS 9011
- CAS-184475-35-2
Reported adverse events
- Conjunctivitis
- Keratitis
- Proteinuria
- Skin reaction
- Stomatitis
- Vomiting
- Nail disorder
- Acne
- Acne pustular
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Blepharitis
Look up GEFITINIB in the interactive SynDRA portal →